Recent Posts

FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia

The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Read more: https://www.healio.com/hematology-oncology/leukemia/news/online/%7Bd076ee13-cf60-4cb3-9968-78d2cbf0a76f%7D/fda-expands-sprycel-approval-to-include-certain-children-with-acute-lymphoblastic-leukemia

Archive